STOCK TITAN
  1. Home
  2. News
  3. PROC

Procaps Group, S.A. Ordinary Shares - PROC STOCK NEWS

Welcome to our dedicated page for Procaps Group, S.A. Ordinary Shares news (Ticker: PROC), a resource for investors and traders seeking the latest updates and insights on Procaps Group, S.A. Ordinary Shares stock.

Procaps Group, S.A. is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. With significant presence in over 50 countries across all five continents, Procaps Group has established itself as a key player in the healthcare industry. The company is headquartered in Latin America and has direct operations in 13 countries in the region.

Procaps Group engages in the development, manufacturing, and marketing of a wide range of products, including over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company operates through several segments, notably NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. Among these, the Procaps Colombia segment generates the highest revenue.

Procaps Group prides itself on its sustainable business model and employs over 5,000 collaborators globally. Their innovation-driven approach has resulted in numerous recent achievements and ongoing projects aimed at enhancing healthcare delivery and accessibility.

For investors looking to stay updated on Procaps Group's performance, the company consistently releases the latest news and updates, detailing their financial condition, new partnerships, product launches, and other significant developments. This ensures transparency and keeps shareholders well-informed.

Whether you're looking for in-depth information on the company or the latest updates on their stock performance, Procaps Group, S.A. remains a reliable source of pharmaceutical advancements and an important player in the global healthcare market.

News

Procaps Group Reports Third Quarter 2023 Results

Rhea-AI Summary
Procaps Group, S.A. (NASDAQ: PROC) reported a 5% increase in net revenues for 9M23 year-over-year on a constant currency basis, driven by 13% RX growth. The company's gross margin was 56% for 9M23, with an adjusted EBITDA of $51 million. The CEO announced a transition to Executive Chairman and a new CEO appointment. The company revised its full-year 2023 guidance, expecting a net revenues growth of approximately 6% on a constant currency basis and an adjusted EBITDA in the range of $77M - $82M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
earnings
-
News

Statement from the Board of Directors of Procaps Group

Rhea-AI Summary
Procaps Group (NASDAQ: PROC) announced the transition of Ruben Minski from CEO to Executive Chairman of the Board, highlighting his leadership and achievements over the past four decades. The company has achieved significant milestones, including FDA certification for RX products and listing on Nasdaq in 2021. With a presence in 13 countries and a robust pipeline of over 100 products under development, Procaps is focused on long-term growth and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
management
-
News

Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America

Rhea-AI Summary
Procaps Group (PROC) and Genomma Lab Internacional (LABB) have announced a strategic agreement to develop, manufacture, and market five Softgel products within Latin America. Procaps will manufacture, and Genomma will market and distribute the products, leveraging Genomma’s marketing and distribution network to reach new customers. This collaboration aims to access new markets and introduce innovative oral delivery systems across a wide distribution network of independent and chain pharmacy retailers, wholesalers, and e-commerce channels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
News

Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024

Rhea-AI Summary
Procaps Group (PROC) Announces Strategic Leadership Transition with New CEO Jose Antonio Vieira
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.4%
Tags
management
-
News

Procaps Group Update on Third Quarter Results

Rhea-AI Summary
Procaps Group (NASDAQ: PROC) Postpones Earnings Conference Call for 3Q23 Results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.03%
Tags
earnings
-
News

Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023

Rhea-AI Summary
Procaps Group (NASDAQ: PROC) to host conference call on November 16, 2023, at 10:30 a.m. Eastern Time to discuss third quarter and nine months 2023 results. The leading integrated LatAm healthcare and pharmaceutical services company will report its financial results for the period ended September 30, 2023, after market closes on November 14, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.28%
Tags
conferences
News

Procaps Group Wins First Place in Ranking of Innovative Companies in the Pharma Sector in Colombia

Rhea-AI Summary
Procaps Group has been ranked first among companies in the pharmaceutical segment in Colombia for the 5th consecutive year. The ranking was conducted by the National Business Association of Colombia (ANDI) and Dinero magazine, evaluating over 250 businesses based on conditions necessary for innovation. Procaps received recognition for its team's innovative vision and accomplishments, reflecting its dedication to delivering health and nutrition globally. The company has a direct presence and exports to more than 50 countries worldwide, with over 40 granted patents on oral delivery system technologies and continuous development of new patents. Procaps was also certified for its Innovation Management System and recognized for its great culture of innovation by the Great Place to Work Institute and the Ministry of Sciences, Technology and Innovation of Colombia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
-
News

Procaps Appoints Sandra Sánchez y Oldenhage to Board of Directors

Rhea-AI Summary
Procaps Group has announced the appointment of Sandra Sánchez y Oldenhage as a Director to its Board of Directors. Sandra brings over 35 years of experience in the pharmaceutical industry and has held various leadership positions in major companies. Her appointment is expected to contribute to the growth and expansion of Procaps.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.84%
Tags
management
-
News

Procaps Group to Participate at CPHI Barcelona 2023

Rhea-AI Summary
Procaps Group announces participation at CPHI Barcelona 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
conferences
News

Procaps Group to Host Webinar on Colombian Pharma Market

Rhea-AI Summary
Procaps Group (NASDAQ: PROC) will host a webinar on October 10th to discuss the Colombian pharma market and its regulations. The webinar will be led by Mariana Sarasti, Director of Pharmaceutical Industry Chamber within the National Business Association of Colombia (ANDI).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences

FAQ

What is the current stock price of Procaps Group, S.A. Ordinary Shares (PROC)?

The current stock price of Procaps Group, S.A. Ordinary Shares (PROC) is $1.766 as of November 1, 2024.

What is the market cap of Procaps Group, S.A. Ordinary Shares (PROC)?

The market cap of Procaps Group, S.A. Ordinary Shares (PROC) is approximately 205.3M.

What does Procaps Group, S.A. specialize in?

Procaps Group, S.A. specializes in the development, manufacturing, and marketing of pharmaceutical and nutraceutical solutions, including OTC and prescription drugs, nutritional supplements, and high-potency clinical solutions.

In how many countries does Procaps Group, S.A. operate?

Procaps Group, S.A. has a direct presence in 13 countries in Latin America and its products reach over 50 countries worldwide.

What are the main business segments of Procaps Group, S.A.?

The main business segments of Procaps Group include NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics.

How many employees does Procaps Group, S.A. have?

Procaps Group, S.A. employs over 5,000 collaborators globally.

What types of products does Procaps Group, S.A. offer?

Procaps Group offers a range of products including over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions.

Which segment generates the most revenue for Procaps Group, S.A.?

The Procaps Colombia segment generates the most revenue for the company.

How does Procaps Group, S.A. ensure sustainability in its operations?

Procaps Group follows a sustainable business model and is committed to innovation-driven approaches to enhance healthcare delivery and accessibility.

Where is Procaps Group, S.A. headquartered?

Procaps Group, S.A. is headquartered in Latin America.

How can I stay updated on Procaps Group, S.A.'s latest news and developments?

You can stay updated by following the latest news releases and updates published by Procaps Group, S.A., which detail their financial condition, new partnerships, product launches, and other significant developments.

What is the ticker symbol for Procaps Group, S.A. on the stock market?

The ticker symbol for Procaps Group, S.A. on the stock market is PROC.

Stock PROC logo
Procaps Group, S.A. Ordinary Shares

Nasdaq:PROC

PROC Rankings

#3821 Ranked by Market Cap
N/A Ranked by Dividends

PROC Stock Data

205.34M
112.82M
83.03%
2.94%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Luxembourg